Navigation Links
Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
Date:2/1/2010

dicine (CIRM) Independent Citizens' Oversight Committee.

Dr. Kauffman joined Onyx in November 2009 as Interim Chief Medical Officer.  Most recently, Dr. Kauffman was Chief Medical Officer at Proteolix, Inc. where he was responsible for the clinical advancement of carfilzomib as well as their other pipeline candidates.  Previously, Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008.  From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., where he played a key role in the development of the proteasome inhibitor VELCADE®.  Earlier in his career, he served as Medical Director at Biogen Corporation (now Biogen Idec).  Dr. Kauffman earned his undergraduate degree in biochemistry from Amherst College and his M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins.  He trained in Internal Medicine and Rheumatology at Beth Israel Deaconess Hospital and the Massachusetts General Hospital.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer.  The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types.  Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
2. China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
3. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
4. Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
5. Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
6. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
7. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
8. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
9. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
10. Poniard Pharmaceuticals Announces $6.5 Million Financing
11. Titan Pharmaceuticals to Receive $3 Million Loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 2015 , ... MediVet Biologics, a leader in Veterinary Regenerative ... open in Manhattan, Kansas in early October, 2015. The location of the lab ... development through collaboration with researchers from Kansas State University’s College of Veterinary Medicine. ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
(Date:8/26/2015)... China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has been informed that Magnum Opus ... by Mr. Yuen Kam, chairman of the board of ... (the "Shares") of  Excellent China Healthcare Investment Limited ("KKR ...
(Date:8/26/2015)... ... ... The 2015 Epigenomics & Metabolomics Meeting in Boston was an ideal ... share the first report on progress with its crowdsourcing campaign designed to evaluate rapidly ... , With a name like “H2A.Z asymmetry,” the new biomarker would require detailed explication ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... Christine Lawless, MD, has accepted the position as Medical ... medical education (CME), beginning March 2, 2009. Recognized as ... cardiology, Dr. Lawless recently completed her clinical tenure at ... she was Associate Professor of Internal Medicine and Co-Director ...
... March 10 SeqWright, a world-wide leader in custom ... has been granted a California clinical laboratory license. ... and Single Nucleotide Polymorphism (SNP) Genotyping expertise in order ... a significant step forward in the shift towards personalized ...
... American Pacific Corporation (Nasdaq: APFC ) is ... Chemicals LLC (AFC), located near Sacramento California, recently inaugurated ... The new facility can accommodate either batch reactors (20 ... using up to 7 reactors from 0.25 to 1 ...
Cached Biology Technology:Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2California Grants SeqWright License to Operate as a Clinical Laboratory 2AMPAC Fine Chemicals Announces the Inauguration of the New cGMP Continuous Processing Development Facility 2
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... CHAMPAIGN, Ill. University of Illinois researchers are using ... weightiest questions in biology the relationship between cell mass ... computer engineering and bioengineering professor Rashid Bashir, published its results ... the National Academy of Sciences . "It,s merging micro-scale ...
... , LA JOLLA, CA-Fisetin, a naturally occurring compound ... slows the onset of motor problems and delays ... to researchers at the Salk Institute for Biological ... of Human Molecular Genetics , sets the ...
... ovarian cancer but new research from the Centenary Institute has ... new way that can break the resistance mechanism. Published ... (FTY720) had a potent effect in human ovarian cancer cells, ... chemotherapeutic drug currently available for the treatment of ovarian cancer. ...
Cached Biology News:Microsensors offer first look at whether cell mass affects growth rate 2Natural compound shows promise against Huntington's disease 2Natural compound shows promise against Huntington's disease 3New treatment to overpower drug resistance in ovarian cancer 2
... consist of seven reduced, denatured proteins (equine ... rabbit muscle GAPDH, bovine muscle actin, BSA, ... ranging from 4.5 to 8.5 and molecular ... 2-D standards provide calibrated references for the ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI)...
Biology Products: